Harrisson S et al. Six month interim results of MSDC-0602K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444). (Abstract PS-111)
Nirsevimab beschermt tegen ondersteluchtweginfectie door RS-virus
okt 2021 | Virale infecties